Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 560

1.

Response to Comment on Davis et al. Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: the Fremantle Diabetes Study Phase I. Diabetes Care 2018;42:102-109.

Davis WA, Hamilton EJ, Bruce DG, Davis TME.

Diabetes Care. 2019 Jun;42(6):e101. doi: 10.2337/dci19-0015. No abstract available.

PMID:
31110125
2.

Cosmological Constraints from Multiple Probes in the Dark Energy Survey.

Abbott TMC, Alarcon A, Allam S, Andersen P, Andrade-Oliveira F, Annis J, Asorey J, Avila S, Bacon D, Banik N, Bassett BA, Baxter E, Bechtol K, Becker MR, Bernstein GM, Bertin E, Blazek J, Bridle SL, Brooks D, Brout D, Burke DL, Calcino J, Camacho H, Campos A, Carnero Rosell A, Carollo D, Carrasco Kind M, Carretero J, Castander FJ, Cawthon R, Challis P, Chan KC, Chang C, Childress M, Crocce M, Cunha CE, D'Andrea CB, da Costa LN, Davis C, Davis TM, De Vicente J, DePoy DL, DeRose J, Desai S, Diehl HT, Dietrich JP, Dodelson S, Doel P, Drlica-Wagner A, Eifler TF, Elvin-Poole J, Estrada J, Evrard AE, Fernandez E, Flaugher B, Foley RJ, Fosalba P, Frieman J, Galbany L, García-Bellido J, Gatti M, Gaztanaga E, Gerdes DW, Giannantonio T, Glazebrook K, Goldstein DA, Gruen D, Gruendl RA, Gschwend J, Gutierrez G, Hartley WG, Hinton SR, Hollowood DL, Honscheid K, Hoormann JK, Hoyle B, Huterer D, Jain B, James DJ, Jarvis M, Jeltema T, Kasai E, Kent S, Kessler R, Kim AG, Kokron N, Krause E, Kron R, Kuehn K, Kuropatkin N, Lahav O, Lasker J, Lemos P, Lewis GF, Li TS, Lidman C, Lima M, Lin H, Macaulay E, MacCrann N, Maia MAG, March M, Marriner J, Marshall JL, Martini P, McMahon RG, Melchior P, Menanteau F, Miquel R, Mohr JJ, Morganson E, Muir J, Möller A, Neilsen E, Nichol RC, Nord B, Ogando RLC, Palmese A, Pan YC, Peiris HV, Percival WJ, Plazas AA, Porredon A, Prat J, Romer AK, Roodman A, Rosenfeld R, Ross AJ, Rykoff ES, Samuroff S, Sánchez C, Sanchez E, Scarpine V, Schindler R, Schubnell M, Scolnic D, Secco LF, Serrano S, Sevilla-Noarbe I, Sharp R, Sheldon E, Smith M, Soares-Santos M, Sobreira F, Sommer NE, Swann E, Swanson MEC, Tarle G, Thomas D, Thomas RC, Troxel MA, Tucker BE, Uddin SA, Vielzeuf P, Walker AR, Wang M, Weaverdyck N, Wechsler RH, Weller J, Yanny B, Zhang B, Zhang Y, Zuntz J; DES Collaboration.

Phys Rev Lett. 2019 May 3;122(17):171301. doi: 10.1103/PhysRevLett.122.171301.

PMID:
31107093
3.

Subjective memory complaints are not increased in type 2 diabetes: A matched cohort study.

Bruce DG, Davis WA, Hunter ML, Davis TME.

J Diabetes Complications. 2019 Jun;33(6):424-426. doi: 10.1016/j.jdiacomp.2019.04.001. Epub 2019 Apr 7.

PMID:
31054798
4.

The LEADER trial in type 2 diabetes: Were the characteristics and outcomes of the participants representative?

Davis TME, Davis WA.

J Diabetes Complications. 2019 Jun;33(6):427-433. doi: 10.1016/j.jdiacomp.2019.03.005. Epub 2019 Mar 25.

PMID:
31003926
5.

Dementia complicating type 2 diabetes and the influence of premature mortality: the Fremantle Diabetes Study.

Bruce DG, Davis TME, Davis WA.

Acta Diabetol. 2019 Jul;56(7):767-776. doi: 10.1007/s00592-019-01322-9. Epub 2019 Apr 3.

PMID:
30945048
6.

Contribution of Malaria to Inhospital Mortality in Papua New Guinean Children from a Malaria-Endemic Area: A Prospective Observational Study.

Laman M, Aipit S, Bona C, Aipit J, Davis TME, Manning L.

Am J Trop Med Hyg. 2019 Apr;100(4):835-841. doi: 10.4269/ajtmh.18-0769.

PMID:
30793683
7.

Impact of an Active Music Therapy Intervention on Intensive Care Patients.

Golino AJ, Leone R, Gollenberg A, Christopher C, Stanger D, Davis TM, Meadows A, Zhang Z, Friesen MA.

Am J Crit Care. 2019 Jan;28(1):48-55. doi: 10.4037/ajcc2019792.

PMID:
30600227
8.

Incidence and Determinants of Intraocular Lens Implantation in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.

Drinkwater JJ, Davis TME, Turner AW, Bruce DG, Davis WA.

Diabetes Care. 2019 Feb;42(2):288-296. doi: 10.2337/dc18-1556. Epub 2018 Dec 6.

PMID:
30523034
9.

Ertapenem for osteoarticular infections in obese patients: a pharmacokinetic study of plasma and bone concentrations.

Chambers J, Page-Sharp M, Salman S, Dyer J, Davis TME, Batty KT, Manning L.

Eur J Clin Pharmacol. 2019 Apr;75(4):511-517. doi: 10.1007/s00228-018-2597-z. Epub 2018 Dec 4.

PMID:
30511329
10.

Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: The Fremantle Diabetes Study Phase I.

Davis WA, Hamilton EJ, Bruce DG, Davis TME.

Diabetes Care. 2019 Jan;42(1):102-109. doi: 10.2337/dc18-1486. Epub 2018 Nov 19.

PMID:
30455327
11.

Temporal changes in the incidence and predictors of severe hypoglycaemia in type 2 diabetes: The Fremantle Diabetes Study.

Davis TME, Bruce DG, Finn J, Curtis BH, Barraclough H, Davis WA.

Diabetes Obes Metab. 2019 Mar;21(3):648-657. doi: 10.1111/dom.13568. Epub 2018 Nov 25.

PMID:
30370611
12.

Acquisition of Antibodies Against Endothelial Protein C Receptor-Binding Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1 in Children with Severe Malaria.

Rambhatla JS, Turner L, Manning L, Laman M, Davis TME, Beeson JG, Mueller I, Warrel J, Theander TG, Lavstsen T, Rogerson SJ.

J Infect Dis. 2019 Feb 15;219(5):808-818. doi: 10.1093/infdis/jiy564.

PMID:
30365003
13.

Response to Letter to the Editor: "Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men".

Lamb LS, Davis TME, Forbes J, Irrgang F, Golledge J, Flicker L, Yeap BB.

J Clin Endocrinol Metab. 2019 Mar 1;104(3):684-685. doi: 10.1210/jc.2018-02198. No abstract available.

PMID:
30351368
14.

Pharmacotherapy for the prevention of malaria in pregnant women: currently available drugs and challenges.

Moore BR, Davis TME.

Expert Opin Pharmacother. 2018 Nov;19(16):1779-1796. doi: 10.1080/14656566.2018.1526923. Epub 2018 Oct 5. Review.

PMID:
30289730
15.

A systematic review of risk factors for cataract in type 2 diabetes.

Drinkwater JJ, Davis WA, Davis TME.

Diabetes Metab Res Rev. 2019 Jan;35(1):e3073. doi: 10.1002/dmrr.3073. Epub 2018 Sep 27.

PMID:
30209868
16.

Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men.

Lamb LS, Alfonso H, Norman PE, Davis TME, Forbes J, Müench G, Irrgang F, Almeida OP, Golledge J, Hankey GJ, Flicker L, Yeap BB.

J Clin Endocrinol Metab. 2018 Nov 1;103(11):4224-4231. doi: 10.1210/jc.2018-00674.

PMID:
30137355
17.

A 10-Year Prospective Study of Bone Mineral Density and Bone Turnover in Males and Females With Type 1 Diabetes.

Hamilton EJ, Drinkwater JJ, Chubb SAP, Rakic V, Kamber N, Zhu K, Prince RL, Davis WA, Davis TME.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3531-3539. doi: 10.1210/jc.2018-00850.

PMID:
30032248
18.

Validation of a Dried Blood Spot Ceftriaxone Assay in Papua New Guinean Children with Severe Bacterial Infections.

Mukap M, Sprod C, Tefuarani N, Laman M, Page-Sharp M, Salman S, Moore BR, Batty KT, Davis TME, Manning L.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00940-18. doi: 10.1128/AAC.00940-18. Print 2018 Oct.

19.

Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.

Bruce DG, Davis WA, Davis TME.

Diabetes Obes Metab. 2018 Dec;20(12):2852-2859. doi: 10.1111/dom.13469. Epub 2018 Aug 10.

20.

Apoptosis inhibitor of macrophage and diabetic kidney disease.

Davis TME, Peters KE, Lipscombe R.

Cell Mol Immunol. 2019 May;16(5):521. doi: 10.1038/s41423-018-0088-x. Epub 2018 Jul 12. No abstract available.

PMID:
30002449
21.

The relationship between circulating adiponectin, ADIPOQ variants and incident cardiovascular disease in type 2 diabetes: The Fremantle Diabetes Study.

Peters KE, Davis WA, Beilby J, Hung J, Bruce DG, Davis TME.

Diabetes Res Clin Pract. 2018 Sep;143:62-70. doi: 10.1016/j.diabres.2018.06.005. Epub 2018 Jun 30.

PMID:
29969725
22.

Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.

Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Friberg Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J.

PLoS Med. 2018 Jun 12;15(6):e1002579. doi: 10.1371/journal.pmed.1002579. eCollection 2018 Jun.

23.

CIP2A immunosensor comprised of vertically-aligned carbon nanotube interdigitated electrodes towards point-of-care oral cancer screening.

Ding S, Das SR, Brownlee BJ, Parate K, Davis TM, Stromberg LR, Chan EKL, Katz J, Iverson BD, Claussen JC.

Biosens Bioelectron. 2018 Oct 15;117:68-74. doi: 10.1016/j.bios.2018.04.016. Epub 2018 Apr 8.

PMID:
29886188
24.

The relationship between intensification of blood glucose-lowering therapies, health status and quality of life in type 2 diabetes: The Fremantle Diabetes Study Phase II.

Davis TME, Bruce DG, Curtis BH, Barraclough H, Davis WA.

Diabetes Res Clin Pract. 2018 Aug;142:294-302. doi: 10.1016/j.diabres.2018.05.047. Epub 2018 Jun 4.

PMID:
29879496
25.

Clinical risk factors for depressive syndrome in Type 2 diabetes: the Fremantle Diabetes Study.

Bruce DG, Davis WA, Starkstein SE, Davis TME.

Diabet Med. 2018 Jul;35(7):903-910. doi: 10.1111/dme.13631. Epub 2018 May 2.

PMID:
29608787
26.

Hippocampal atrophy, asymmetry, and cognition in type 2 diabetes mellitus.

Milne NT, Bucks RS, Davis WA, Davis TME, Pierson R, Starkstein SE, Bruce DG.

Brain Behav. 2017 Dec 22;8(1):e00741. doi: 10.1002/brb3.741. eCollection 2018 Jan.

27.

The utility of the Diabetes Anxiety Depression Scale in Type 2 diabetes mellitus: The Fremantle Diabetes Study Phase II.

Davis WA, Bruce DG, Dragovic M, Davis TME, Starkstein SE.

PLoS One. 2018 Mar 15;13(3):e0194417. doi: 10.1371/journal.pone.0194417. eCollection 2018.

28.

Hearing Loss in Adults.

Davis TM, Davis WA, Hunter M.

N Engl J Med. 2018 Mar 8;378(10):970. doi: 10.1056/NEJMc1800570. No abstract available.

PMID:
29514036
29.

Author reply.

Davis TME.

Intern Med J. 2018 Mar;48(3):367-368. doi: 10.1111/imj.13721. No abstract available.

PMID:
29512319
30.

Prevalence of diabetes in Australia: insights from the Fremantle Diabetes Study Phase II.

Davis WA, Peters KE, Makepeace A, Griffiths S, Bundell C, Grant SFA, Ellard S, Hattersley AT, Paul Chubb SA, Bruce DG, Davis TME.

Intern Med J. 2018 Jul;48(7):803-809. doi: 10.1111/imj.13792.

31.

Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.

Waldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L, Davis TME, Best JD, Li L, Feher MD, Foucher C, Kesaniemi YA, Flack J, d'Emden MC, Scott RS, Hedley J, Gebski V, Keech AC; FIELD investigators.

Lancet Diabetes Endocrinol. 2018 Apr;6(4):310-318. doi: 10.1016/S2213-8587(18)30029-9. Epub 2018 Feb 26.

PMID:
29496472
32.

Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II.

Keen HI, Davis WA, Latkovic E, Drinkwater JJ, Nossent J, Davis TME.

J Diabetes Complications. 2018 Apr;32(4):400-405. doi: 10.1016/j.jdiacomp.2017.12.015. Epub 2018 Jan 5.

PMID:
29483015
33.

Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Davis TME, Mulder H, Lokhnygina Y, Aschner P, Chuang LM, Raffo Grado CA, Standl E, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2018 Jun;20(6):1427-1434. doi: 10.1111/dom.13242. Epub 2018 Feb 28.

PMID:
29405540
34.

Artemisinin Therapy for Malaria in Hemoglobinopathies: A Systematic Review.

Sugiarto SR, Moore BR, Makani J, Davis TME.

Clin Infect Dis. 2018 Feb 10;66(5):799-804. doi: 10.1093/cid/cix785.

PMID:
29370347
35.

Methicillin-resistant Staphylococcus aureus in Papua New Guinea: a community nasal colonization prevalence study.

Laman M, Greenhill A, Coombs GW, Robinson O, Pearson J, Davis TME, Manning L.

Trans R Soc Trop Med Hyg. 2017 Aug 1;111(8):360-362. doi: 10.1093/trstmh/trx061.

PMID:
29237065
36.

Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: the Fremantle Diabetes Study.

Davis TME, Chubb SAP, Curtis BH, Barraclough H, Davis WA.

Intern Med J. 2018 Oct;48(10):1215-1221. doi: 10.1111/imj.13710.

PMID:
29230931
37.

XTHs from Fragaria vesca: genomic structure and transcriptomic analysis in ripening fruit and other tissues.

Opazo MC, Lizana R, Stappung Y, Davis TM, Herrera R, Moya-León MA.

BMC Genomics. 2017 Nov 7;18(1):852. doi: 10.1186/s12864-017-4255-8.

38.

Cost-effectiveness of artemisinin-naphthoquine versus artemether-lumefantrine for the treatment of uncomplicated malaria in Papua New Guinean children.

Moore BR, Davis WA, Clarke PM, Robinson LJ, Laman M, Davis TME.

Malar J. 2017 Oct 30;16(1):438. doi: 10.1186/s12936-017-2081-8.

39.

Regarding "Lactation Status and Studies of Pyrimethamine Pharmacokinetics in Pregnancy".

Salman S, Davis TME.

CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):730. doi: 10.1002/psp4.12257. Epub 2017 Oct 24. No abstract available.

40.

Risk and associates of incident hip fracture in type 1 diabetes: The Fremantle Diabetes Study.

Hamilton EJ, Davis WA, Bruce DG, Davis TME.

Diabetes Res Clin Pract. 2017 Dec;134:153-160. doi: 10.1016/j.diabres.2017.10.011. Epub 2017 Oct 18.

PMID:
29054483
41.
42.

Feasibility of a multi-modal exercise program on cognition in older adults with Type 2 diabetes - a pilot randomised controlled trial.

Callisaya ML, Daly RM, Sharman JE, Bruce D, Davis TME, Greenaway T, Nolan M, Beare R, Schultz MG, Phan T, Blizzard LC, Srikanth VK.

BMC Geriatr. 2017 Oct 16;17(1):237. doi: 10.1186/s12877-017-0635-9.

43.

Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations.

Sugiarto SR, Davis TME, Salman S.

Expert Opin Drug Metab Toxicol. 2017 Nov;13(11):1115-1133. doi: 10.1080/17425255.2017.1391212. Epub 2017 Oct 20. Review.

PMID:
29027504
44.

The prevalence of monogenic diabetes in Australia: the Fremantle Diabetes Study Phase II.

Davis TM, Makepeace AE, Ellard S, Colclough K, Peters K, Hattersley A, Davis WA.

Med J Aust. 2017 Oct 16;207(8):344-347.

PMID:
29020906
45.

Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II.

Davis TME, Kauhanen J, Davis WA.

Intern Med J. 2017 Oct;47(10):1206-1210. doi: 10.1111/imj.13569.

PMID:
28994256
46.

Recommendations from the First National Academic Consortium of Telehealth.

Hollander JE, Davis TM, Doarn C, Goldwater JC, Klasko S, Lowery C, Papanagnou D, Rasmussen P, Sites FD, Stone D, Carr BG.

Popul Health Manag. 2018 Aug;21(4):271-277. doi: 10.1089/pop.2017.0080. Epub 2017 Oct 4.

PMID:
28976250
47.

Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II.

Peters KE, Davis WA, Ito J, Winfield K, Stoll T, Bringans SD, Lipscombe RJ, Davis TME.

Diabetes Care. 2017 Nov;40(11):1548-1555. doi: 10.2337/dc17-0911. Epub 2017 Aug 29.

PMID:
28851702
48.

Bradycardia and Hypothermia Complicating Azithromycin Treatment.

Benn K, Salman S, Page-Sharp M, Davis TME, Buttery JP.

Am J Case Rep. 2017 Aug 11;18:883-886.

49.

Two-year audit of outcomes of pituitary surgery at an Australian teaching hospital.

Davis TME, Badshah I, Drinkwater J, Kusich E, Latkovic E, Knuckey N.

Intern Med J. 2017 Nov;47(11):1248-1255. doi: 10.1111/imj.13546.

PMID:
28675669
50.

Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling.

Salman S, Baiwog F, Page-Sharp M, Kose K, Karunajeewa HA, Mueller I, Rogerson SJ, Siba PM, Ilett KF, Davis TME.

Int J Antimicrob Agents. 2017 Oct;50(4):542-551. doi: 10.1016/j.ijantimicag.2017.05.011. Epub 2017 Jun 29.

PMID:
28669839

Supplemental Content

Loading ...
Support Center